1. The effects of timolol alone and in combination with a fixed dose of hydrochlorothiazide and amiloride have been studied in a doubleblind, controlled study in fifty-four patients with mild to moderate essential hypertension.
Introduction
Timolol has been shown to be effective in the management of the majority of patients with essential hypertension at an average dose of about 30 mglday, given in either two or three doses (Louis, Morgan, Anavekar & Doyle, 1974; Franciosa, Freis & Conway, 1973) . It has also been shown that the average effective dose of timolol can be lowered to about 20 mg/day (either in two or three doses) by the concomitant administration of hydrochlorothiazide, 50 mg/day (Pyorala, Mattila, Leirisalo & Taivonen, 1974) .
It is now a wellestablished practice to use a potassium-sparing agent such as amiloride in combination with hydrochlorothiazide to counteract the potassium loss encountered with the use of thiazide diuretics. Therefore, the combination of timolol, hydrochlorothiazide and amiloride is a rational approach to the management of hypertension. The purpose of this study was to determine if a significant anti-hypertensive and potassium-sparing effect is associated with the administration of tirnolol, hydrochlorothiazide and amiloride in a combination tablet as compared with hydrochlorothiazidel amiloride and to timolol in patients with mild to moderate hypertension. These results, obtained as a part of a multi-clinic study involving seventeen investigators, were obtained from two of the clinics.
Materials and methods
Patients with mild to moderate essential hypertension (WHO stages I and 11) were admitted to the study. Patients with secondary hypertension or in whom /?-receptor-blocker or hydrochlorothiazide therapy was contraindicated were excluded.
After 4 weeks on placebo (one tablet twice daily), fifty-four patients (thirty-two female and twentytwo male; mean age 48.5 years) with diastolic blood pressures between 105 and 140 mmHg were randomly assigned to one of three treatment groups :
Group A. Timolol 10 mg twice daily correspond-
ing to a total daily dose of 20 mg: eighteen patients, average age 47.9 years (range 26-59 years). Group B. Hydrochlorothiazide/amiloride in one tablet 25/2.5 mg twice daily corresponding to a total daily dose of 50 mg of hydrochlorothiazide and 5 mg of amiloride: eighteen patients, average age 51.8 years (range 40-60 years).
Group C. Timolol/hydrochlorothiazide/amiloride in one tablet 10/25/2.5 mg twice daily corresponding to a total daily dose of 20 mg of timolol, 50 mg of hydrochlorothiazide and 5 mg of amiloride: eighteen patients, average age 44.9 years (range 31-56 years). All tablets were identical in appearance and their contents were not disclosed to the physicians or to the patients until the end of the study. The patients were treated for 6 weeks. Patients were seen every 2 weeks throughout the study, at which times they were given a physical examination and their blood pressures were recorded in both the supine and standing positions. Three consecutive readings were taken in each position with the last two averaged. Laboratory examinations were done at the second and fourth weeks on placebo and after 2 and 6 weeks on active drug. Side effects were recorded both as observed by the physicians and as reported by the patients.
The effectiveness of the therapy was evaluated by the decrease in mean supine diastolic blood pressures from the end of the placebo period (base line) to the end of the study (6 weeks on therapy). Patients whose supine diastolic blood pressure was 90 mmHg or less were considered to be normotensive. Responders were defined as those patients who had a decrease in supine diastolic blood pressure from base line of 10 mmHg or more. At the end of week 10, patients ofgroups A and B with a supine diastolic blood pressure 3 9 5 mmHg, and group C patients with a supine diastolic blood pressure ~9 5 mmHg, were maintained on timolol/hydrochlorothiazide/ amiloride for 14 weeks. Statistical assessment of the data was performed by analysis of variance. Fisher's test was used for the comparison between variances. Student's 1-test was used to evaluate the differences between the mean values for each variable at the end of period 2 (group C vs groups A and B). blind period heart rate was significantly reduced in groups A and C. The greatest reduction was in group A. Standing and supine systolic blood pressure was lower in group C than in groups A and B.
Standing and supine diastolic blood pressure decrease was greater in group C than in groups A and B. Plasma potassium did not decrease significantly in groups A, B and C at the end of the double-blind period. Only one patient (group C) had an abnormally high blood uric acid value (7.9 mg/100 ml). A total of fourteen patients had clinical side effects:
three in group A, five in group B and six in group C.
The most common side effects reported were asthenia and fatigue: three in group A, one in group B and six in group C. With the exception of one patient in group C all the side effects were mild to moderate in intensity and of short duration, and the patients recovered without reduction or interruption of the dosage. In the patients who entered the open study period an increase of the anti-hypertensive effect was observed without the appearance of clinical and laboratory side effects.
Results are shown in Table 1 .
Discussion
The use of timolol (10 mg), hydrochlorothiazide (25 mg) and amiloride (2.5 mg) in a combination tablet given twice daily gave a better control of blood pressure in patients with mild to moderate essential hypertension than did equivalent doses of t imolol alone or hydrochlorothiazide/amiloride.
The clinical side effects and laboratory abnormalities seen were minimal and those to be expected with a Bblocker and a thiazide diuretic. A slight decrease of plasma potassium values (P < 0.05) was seen only in group B patients at the end of the 14 weeks open period.
Some patients noted a feeling of well-being while on timolol alone or in combination. This was at least in part due to the disappearance of headaches, but it might also be related to a specific action of the drug on the central nervous system.
